TECH CONNECT
Turning Ideas into Opportunities
Monthly news & updates


June 1, 2021
Vanderbilt startup HeroWear releases 1-year update video
CTTC’s Brad Baird Elected to the 2021 Inteum Global User Group
Brad Baird, CTTC's Database Manager, has been elected to the 2021 Inteum Global User Committee. Inteum is the industry-leading intellectual property management software provider used by more than 400 universities, research institutions, and federal labs (from 25+ countries) for managing the bulk of their IP management operations. The purpose of the Inteum User Group Committee is to share best practices, SOP’s and desired functionality ideas with the users and the company, all for the goal of maximizing efficiency to the daily operations of each user’s site. 
Brad has served as CTTC’s Database Manager for twenty years and has led or greatly contributed to the support, security, training, and optimization of Inteum. He has been crucial in the managing and instructional use of Inteum which has led to a consistently high level of accuracy in the data and resulting reports. With his experience and knowledge of Inteum, Brad will be an asset to the global community of IP professionals as part of this Committee.
Five Vanderbilt technologies earn patent protection in May
Weekly Interactions
Below is a sampling of the interactions that have taken place in our office and with our staff over the last month.
ATTENDED
  • Attended webinar by ITIF "The Role of Intellectual Property Rights in Ending the COVID-19 Pandemic"

  • Attended World Vaccine Congress Washington Conference

  • Attended an online OSA/NCATS Tech Transfer Metrics Workshop to hear about technology transfer metrics and ways of measuring efficiencies beyond traditional metrics

  • Attended an online webinar by the Technology Transfer Society with a presentation by Jeffrey Kaplan, head of the Veterans Administration Technology Transfer department, on Tech Transfer at the VA and their determination of rights process

  • Attended webinar series on the Trajectory of Telehealth

  • Attended AUTM Focus Group: Strategic Planning

  • Attended webinar “Financing the Deal: Deal-Making Trends and Strategies for Health Care Companies”

  • Attended the Day of Wond'ry 2021

  • Attended Nashville Healthcare Council Member Speed Networking event

  • Attended The Wond’ry May Innovation Open Mic

  • Attended webinar “Corporate Governance: Fundamentals, Recent Developments, and Confidentiality Considerations”

  • Attended Nashville Private Directors Association Networking event

  • Attended Nashville Entrepreneur Center Member Networking

  • Attended webinar "Risk Management Considerations for Emerging Companies: Is Your Business Covered?"

  • Attended Zavikon/Vanderbilt Driving Simulator Meeting

  • Attended "Governance of Innovation in Portfolios, Programs, and Projects" Webinar
EXECUTED
  • Extended the option term for a chemical engineering technology with Scale Holdings. LLC

  • Executed an option agreement with a small biotech company for small molecule inhibitors of cancer metabolism developed by Charles Manning, formerly of VUIIS

  • Entered into an end-user license for Daniel Fabbri’s “Tool for Automatic Data Curation from Unstructured Text” software with the Dana-Farber Cancer Institute
MARKETED


  • Held a call with the client feedback program of one of CTTC’s approved law firms as part of their routine check-in on service

  • Held an introductory call with an investor group interested in the microbiome to discuss possible areas of collaboration

  • Held a call with Vanderbilt’s liaison at a major international pharmaceutical company regarding an upcoming Request For Applications and their typical areas of interest



  • Held a call with an electronic medical records company to discuss licensing of QPA content developed by Seth Scholer in the Department of Pediatrics

  • Marketed a series of peptide therapeutics developed by Joyce Cheung-Flynn and Colleen Brophy to a biotech venture group focusing on early-stage technologies

  • Met with an exclusive licensee to discuss business development activities, clinical trial progress, and IP strategy

  • Met with a company focusing on identifying, incubating, and accelerating novel technologies in the oncology, neurodegenerative, and rare disease space to discuss potential licensing opportunities

  • Met with the first trainee of the inaugural ASPIRE to Innovate Postdoctoral Fellowship program to discuss projects, program overview, and goals

  • Marketed OrcoGuard technology to a local animal health company


  • Engaged with two early-stage venture investors/technology incubators interested in partnership opportunities with Vanderbilt University and Vanderbilt University Medical Center therapeutic technologies



  • Marketed several technologies to local personalized pharmaceutical company

PARTICIPATED
  • Gave presentation in partnership with MIT and University of Toledo technology transfer office to the Polish Association of Center for Technology Transfer (PACTT) on “United States University Tech Transfer Practices”

  • Gave a presentation to the VUMC Office of Contracts Management on an overview of CTTC and our workflow for reviewing IP terms in research contracts

  • Participated in the "special sections" portion of the most recent Responsible Conduct of Research session for graduate students

  • Hosted a webinar by Derek Stettner from the law firm of Michael Best and Friedrich on the recent supreme court ruling vis-à-vis the Oracle v. Google copyright infringement lawsuit

  • Participated in AbSeek Bio pitch to Alabama PE firm

  • Hosted meeting with VC firm supporting STEM Ph.D. entrepreneurs


  • Participated in pitch for entry of a new company, OrcoGuard, into a national accelerator program

  • CTTC welcomed its summer cohort of interns who will be working with licensing officers on myriad projects to help protect and commercialize Vanderbilt technologies
Technology Pipelines

The pipeline highlights a listing of fully human antibodies by target disease, availability by field, and stage of development. Links to scientific publications are also included.
View our updated Medical Device Pipeline.

The catalogue highlights medical device technologies currently in the pipeline for commercialization at Vanderbilt University. This Pipeline has more than 100 technologies in 12 categories from 40 research groups.

The catalog has more than 60 small molecule therapeutics, 35 biologics and 7 biomarkers that are currently in Vanderbilt's pipeline.